美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · GPCR近 30 天 10 則 · 第 1 / 1 頁
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
- Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
- Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
- Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
- Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
- Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
- Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
- NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
- How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
- LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
- LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
- Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
- Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
- Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
- LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins
- How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
- NVO Rallies 11% in a Month: How Should Investors Play the Stock?
- LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
- This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
- Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。